日本質量分析学会 第67回質量分析総合討論会

Abstract

Oral Sessions

Day 1, May 15(Wed.) 16:05-16:25 Room C (101)

Quantitative Analysis of Oligonucleotide Therapeutics by LC-MS: The Overview of the Discussion in JBF DG

(1CMIC Pharma Science, 2LSI Medience, 3Sumitomo Dainippon Pharma, 4Astellas Pharma, 5Shionogi, 6Kyowa Hakko Kirin, 7Mitsubishi Tanabe Pharm., 8Otsuka Pharmaceutical, 9GlaxoSmithKline)
oYoshiharu Hayashi1, Kouji Arai2, Chihiro Ishikawa3, Fumio Osaki4, Takeo Kamakura5, Asami Toshima6, Hidenori Yasuhara7, Hiroyuki Yokoi8, Akira Wakamatsu9

Japan Bioanalysis Forum (JBF) handles “Discussion Group (DG)” which discusses some issues or questions about bioanalysis in closed with small scale group. Our group (DG36) presented about the topic of “Quantitative analysis of oligonucleotide therapeutics by LC-MS”. The group consisted of nine members. They focused on five themes in which DG members were interested; “sample preparation”, “instrument”, “internal standard”, “validation”, and “comparison with ligand binding assay” and presented an overview of their discussion. Moreover they surveyed the current situation about the quantification of oligonucleotide therapeutics using LC-MS and the results were shared. In this presentation, I will introduce the essence of our report presented in 10th JBF Symposium (held on February 12 - 14, 2019).